Ariel R Green1, Jodi Segal2,3, Jing Tian4, Esther Oh3,5,6, David L Roth1,7, Liam Hilson8, Jennifer L Dodson9, Cynthia M Boyd1,2. 1. Division of Geriatric Medicine and Gerontology, Johns Hopkins University, Baltimore, Maryland. 2. Department of Medicine, Johns Hopkins University, Baltimore, Maryland. 3. Department of Health Policy and Management, Johns Hopkins University, Baltimore, Maryland. 4. Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland. 5. Department of Psychiatry and Behavioral Sciences, School of Medicine, Johns Hopkins University, Baltimore, Maryland. 6. Department of Pathology, School of Medicine, Johns Hopkins University, Baltimore, Maryland. 7. Center on Aging and Health, Johns Hopkins University, Baltimore, Maryland. 8. John A. Burns School of Medicine, University of Hawaii, Honolulu, Haiwaii. 9. Department of Urology, School of Medicine, Johns Hopkins University, Baltimore, Maryland.
Abstract
OBJECTIVE: To examine the use of antimuscarinics for treating urinary incontinence (UI) in older adults with varying levels of cognition. DESIGN: Cross-sectional. SETTING: National Alzheimer's Coordinating Center from 2005 through 2015. PARTICIPANTS: Community-dwelling men and women aged 65 and older (N = 24,106). MEASUREMENTS: Clinicians and staff evaluated each participant's dementia status during annual in-person assessments. Participants or their informants reported all medications taken in the 2 weeks before each study visit. RESULTS: Overall, 5.2% (95% confidence interval (CI) = 4.9-5.5%) of the cohort took a bladder antimuscarinic. Participants with impaired cognition were more likely to be taking an antimuscarinic than those with normal cognition. Rates of bladder antimuscarinic use were 4.0% (95% CI = 3.6-4.4%) for participants with normal cognition, 5.6% (95% CI = 4.9-6.3%) for those with mild cognitive impairment, and 6.0% (95% CI = 5.5-6.4%) for those with dementia (p < .001). Of 624 participants with dementia who took antimuscarinics, 16% (95% CI = 13-19%) were simultaneously taking other medicines with anticholinergic properties. CONCLUSION: Use of bladder antimuscarinics was more common in older adults with impaired cognition than in those with normal cognition. This use is despite guidelines advising clinicians to avoid prescribing antimuscarinics in individuals with dementia because of their vulnerability to anticholinergic-induced adverse cognitive and functional effects. A substantial proportion of cognitively impaired individuals who took antimuscarinics were simultaneously taking other anticholinergic medications. These findings suggest a need to improve the treatment of UI in individuals with impaired cognition.
OBJECTIVE: To examine the use of antimuscarinics for treating urinary incontinence (UI) in older adults with varying levels of cognition. DESIGN: Cross-sectional. SETTING: National Alzheimer's Coordinating Center from 2005 through 2015. PARTICIPANTS: Community-dwelling men and women aged 65 and older (N = 24,106). MEASUREMENTS: Clinicians and staff evaluated each participant's dementia status during annual in-person assessments. Participants or their informants reported all medications taken in the 2 weeks before each study visit. RESULTS: Overall, 5.2% (95% confidence interval (CI) = 4.9-5.5%) of the cohort took a bladder antimuscarinic. Participants with impaired cognition were more likely to be taking an antimuscarinic than those with normal cognition. Rates of bladder antimuscarinic use were 4.0% (95% CI = 3.6-4.4%) for participants with normal cognition, 5.6% (95% CI = 4.9-6.3%) for those with mild cognitive impairment, and 6.0% (95% CI = 5.5-6.4%) for those with dementia (p < .001). Of 624 participants with dementia who took antimuscarinics, 16% (95% CI = 13-19%) were simultaneously taking other medicines with anticholinergic properties. CONCLUSION: Use of bladder antimuscarinics was more common in older adults with impaired cognition than in those with normal cognition. This use is despite guidelines advising clinicians to avoid prescribing antimuscarinics in individuals with dementia because of their vulnerability to anticholinergic-induced adverse cognitive and functional effects. A substantial proportion of cognitively impaired individuals who took antimuscarinics were simultaneously taking other anticholinergic medications. These findings suggest a need to improve the treatment of UI in individuals with impaired cognition.
Authors: Chris C Sexton; Karin S Coyne; Christine Thompson; Tamara Bavendam; Chieh-I Chen; Alayne Markland Journal: J Am Geriatr Soc Date: 2011-06-30 Impact factor: 5.562
Authors: Sandra Weintraub; David Salmon; Nathaniel Mercaldo; Steven Ferris; Neill R Graff-Radford; Helena Chui; Jeffrey Cummings; Charles DeCarli; Norman L Foster; Douglas Galasko; Elaine Peskind; Woodrow Dietrich; Duane L Beekly; Walter A Kukull; John C Morris Journal: Alzheimer Dis Assoc Disord Date: 2009 Apr-Jun Impact factor: 2.703
Authors: Laura K Triantafylidis; Jenna S Clemons; Emily P Peron; John Roefaro; Kristin M Zimmerman Journal: Drugs Aging Date: 2018-01 Impact factor: 3.923